A URL Pharma Inc. unit sued Par Pharmaceutical Cos. (PRX) alleging infringement of 10 patents with its plans to market a generic version of the Colcrys gout treatment.
AR Holding Inc. contends in a complaint filed today in federal court in Wilmington, Delaware, that Par has wrongly applied to the U.S. Food and Drug Administration for approval to sell its copies before the patents expire.
The Wilmington-based holding company “will be irreparably harmed by Par’s infringing activities” unless misuse of the technology is stopped by a judge, it said in court papers.
AR Holding seeks a ruling that Par, of Woodcliff Lake, New Jersey, infringes the patents and asks for unspecified damages and legal fees.
A spokeswoman for Par, Allison Wey, didn’t immediately return a call seeking comment.
Par fell 57 cents, or 1.4 percent, to $39.05 in New York Stock Exchange composite trading at 2:52 p.m.
The case is AR Holding Co. v. Par Pharmaceutical, 12-cv- 419, U.S. District Court, District of Delaware (Wilmington).